Our scientific work includes preclinical studies focusing on immunotherapy, chemotherapy and radiation therapy as well as the improvement of diagnostics. Moreover, basic research in the emerging fields of metastases formation, tumor microenvironment and senescence is currently ongoing in our laboratory. Our experienced radiopharmacy enables us to employ a wide range of conventional and novel PET compounds (referred to as tracers), including [18F]FDG, [18F]FLT and many more. Our group has extensive experience with a wide variety of different tumor models, ranging from classical subcutaneous (s.c.) tumor xenograft models to orthotopic brain tumor models, patient-derived, endogenous, chemically or dietinduced models and transplanted tumors.
In an increasingly interdisciplinary environment, we are not restricted to the well established imaging modalities like PET, MRI (including advanced MRI techniques e.g., apparent diffusion coefficient (ADC) or MR-spectroscopy (MRS)), computed tomography (CT) and single photon emission computed tomography (SPECT). Rather, we attempt to link the imaging data to molecular processes and proteome analysis.